Dr. Naomi Sacks, Vice President, HEORStrategies, a Division of ToxStrategies LLC, is at the annual meeting of ISPOR (The Professional Society for Health Economics and Outcomes Research), which is being held in Atlanta May 5–8, 2024. Dr. Sacks is a co-author on the poster presentation, “Treatment History, Healthcare Resource Use, and Costs Among Patients with Pulmonary Arterial Hypertension (PAH) Initiating Treatment with Macitentan: A Retrospective Claims Analysis.” If you are at ISPOR, reach out to Naomi!

https://www.ispor.org/conferences-education/conferences/upcoming-conferences/ispor-2024

HEORStrategies’ scientist Dr. Naomi Sacks, along with clinicians and industry leaders, is presenting results of a study of antibiotic treatment patterns and treatment failure (TF) in uncomplicated UTI (uUTI) in the US at the 2024 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), held in Barcelona April 27-30. In this study, Sacks and colleagues analyzed US healthcare claims data and found that uUTI patients with treatment failure had higher rates of UTI recurrence, and that patient demographics, including older age and clinical risk factors, may be associated with the risk of TF and recurrent UTI.

HEORStrategies is excited to be attending, exhibiting, and hosting a round table at the World Orphan Drug Congress (WODC), April 23–25, 2024. This year’s congress is at the Boston Convention and Exhibit Center.

Come by and see us at Booth 537!

Also, join us at Roundtable 06, on Wednesday, April 24, at 14:15, when our experts will discuss, “Meeting the Challenges of Fast-Track Approval for Orphan Drugs.” HEORStrategies Vice President, Naomi Sacks, PhD, will be joined by colleagues from ToxStrategies, Modality Solutions, and EpidStrategies to focus on optimal strategies for managing fast-track approval, from pre-clinical through clinical phases of development, regulatory support, and launch.

HEORStrategies’ scientist Dr. Naomi Sacks, along with clinicians and industry leaders, presented study results of uncomplicated UTI (uUTI) in the US and acute cystitis in Japan. In their US-based study, Sacks and colleagues analyzed US healthcare claims data and found that uUTI treatment failure is associated with significantly higher healthcare resource utilization and costs among adult women in the US, highlighting the importance of appropriate empiric antibiotic selection. In their Japan-based study, Sacks and colleagues used Japanese healthcare claims data and found that the burden of acute uncomplicated cystitis is moderate, affecting 6-8.6% of adult Japanese women each year. These studies were presented at IDWeek, October 11-15, 2023.  Please contact Dr. Naomi Sacks at nsacks@heorstrategies.com for additional information.

1. Cost Burden of Patients with Oral Antibiotic Treatment Failure for Uncomplicated Urinary Tract Infection in the United States (Poster 214844)
2. Prevalence of Acute Uncomplicated Cystitis in Japan (Poster 218752)